title: Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.
abstract: OBJECTIVE
  The combination of sorafenib with chemotherapy is well-tolerated and is associated with encouraging response rates in several malignances. Both docetaxel and cisplatin are active in gastric cancer. A phase II study was conducted to determine the efficacy and toxicity of combined sorafenib, docetaxel, and cisplatin in patients with metastatic or advanced adenocarcinoma of stomach or gastroesophageal junction (GEJ).
  
  
  METHODS
  Forty-four chemotherapy-naïve patients with Eastern Cooperative Oncology Group performance status 0 or 1, of whom 80% had metastatic disease and two thirds had poorly differentiated gastric or GEJ adenocarcinoma, were enrolled. The treatment regimen was sorafenib 400 mg orally twice a day for 21 days, docetaxel 75 mg/m(2) intravenously on day 1, and cisplatin 75 mg/m(2) intravenously on day 1, repeated every 21 days. The primary end point was response rate to the combination. Toxicity, overall survival, and progression-free survival were assessed as secondary end points.
  
  
  RESULTS
  Eighteen of the 44 eligible and treated patients showed partial responses (41%; 90% CI, 28% to 54%). The median progression-free survival was 5.8 months (90% CI, 5.4 to 7.4 months). The median overall survival was 13.6 months (90% CI, 8.6 to 16.1 month). The major toxicity of this regimen was neutropenia, which reached grade 3 to 4 in 64% of patients. One patient experienced hemorrhage at the tumor site.
  
  
  CONCLUSIONS
  The combination of sorafenib, docetaxel, and cisplatin has an encouraging efficacy profile with tolerable toxicity. Additional studies of sorafenib with chemotherapy are warranted in gastric cancer.
authors.affiliation: Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104-4283, USA. weijing.sun@uphs.upenn.edu
authors.forename: Weijing
authors.initials: W
authors.lastname: Sun
authors.forename: Mark
authors.initials: M
authors.lastname: Powell
authors.forename: Peter J
authors.initials: PJ
authors.lastname: O'Dwyer
authors.forename: Paul
authors.initials: P
authors.lastname: Catalano
authors.forename: Rafat H
authors.initials: RH
authors.lastname: Ansari
authors.forename: Al B
authors.initials: AB
authors.lastname: Benson
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D004943:Esophagogastric Junction / Q000187:drug effects* / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage; D000077157:Sorafenib; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D043823:Taxoids; D000077143:Docetaxel; D009536:Niacinamide; D000077157:Sorafenib; D002945:Cisplatin
references.citation: N Engl J Med. 2008 Jul 24;359(4):378-90
references.pmid: 18650514
references.citation: J Clin Oncol. 2007 Aug 1;25(22):3217-23
references.pmid: 17664469
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Clin Lung Cancer. 2007 May;8(6):396-8
references.pmid: 17562243
references.citation: N Engl J Med. 2002 Aug 15;347(7):481-7
references.pmid: 12181402
references.citation: Nature. 2002 Jun 27;417(6892):949-54
references.pmid: 12068308
references.citation: N Engl J Med. 2008 Jan 3;358(1):36-46
references.pmid: 18172173
references.citation: J Clin Invest. 2003 May;111(9):1287-95
references.pmid: 12727920
references.citation: Mol Cancer Ther. 2008 Oct;7(10):3129-40
references.pmid: 18852116
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1280-9
references.pmid: 19171708
references.citation: Nat Rev Cancer. 2002 Oct;2(10):795-803
references.pmid: 12360282
references.citation: J Clin Oncol. 2009 Sep 10;27(26):4274-80
references.pmid: 19652055
references.citation: Clin Cancer Res. 2008 Aug 1;14(15):4836-42
references.pmid: 18676756
references.citation: Ann Oncol. 2009 Apr;20(4):666-73
references.pmid: 19153121
references.citation: Br J Cancer. 1999 Apr;80(1-2):269-72
references.pmid: 10390007
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Br J Surg. 1998 Nov;85(11):1457-9
references.pmid: 9823902
references.citation: Eur J Cancer. 2007 Jan;43(1):55-63
references.pmid: 17095207
references.citation: N Engl J Med. 2007 Jan 11;356(2):125-34
references.pmid: 17215530
references.citation: J Clin Oncol. 2006 Nov 1;24(31):4991-7
references.pmid: 17075117
references.citation: Cancer Res. 2004 Oct 1;64(19):7099-109
references.pmid: 15466206